Search research articles
Contact Us
Filters
Showing results (41-50 of 84) with videos related to
Page
of 9
Sort By:
Pulmonary Circulation
|
September 29, 2017
Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension
Jules Hernández-Sánchez, Louise Harlow, Colin Church, et al.
JHLT Open
|
January 22, 2026
Macitentan and phosphodiesterase-5 inhibitor alone or in combination in newly diagnosed pulmonary arterial hypertension: a pooled analysis
Vallerie V McLaughlin, Nicolas Sauvageot, Brian Hennessy, et al.
Plos One
|
April 10, 2015
Elevated plasma CXCL12α is associated with a poorer prognosis in pulmonary arterial hypertension
Brian N McCullagh, Christine M Costello, Lili Li, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation
|
November 16, 2025
Evaluating oral selexipag in pulmonary arterial hypertension: Insights on survival, safety, and dosing patterns from the complete observation period of GRIPHON and its open-label extension
Vallerie V McLaughlin, Luke Howard, Jean Elwing, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation
|
September 2, 2024
Changes in REVEAL Lite 2 risk status are associated with long-term outcomes in patients with pulmonary arterial hypertension: A post-hoc analysis of the GRIPHON study
Raymond L Benza, Kelly M Chin, Sean Gaine, et al.
Thrombosis and Haemostasis
|
January 17, 2025
Treatment of Venous Thromboembolism with Edoxaban over 18 Months: Results from ETNA-VTE Europe
Giancarlo Agnelli, Ulrich Hoffmann, Philippe Hainaut, et al.
Heart Rhythm
|
August 21, 2024
Improved diagnosis of arrhythmogenic right ventricular cardiomyopathy using electrocardiographic deep learning
Richard T Carrick, Eric D Carruth, Alessio Gasperetti, et al.
JHLT Open
|
March 27, 2025
Effects of macitentan and selexipag across prognostic age groups in patients with pulmonary arterial hypertension
Richard Channick, Sarah Medrek, Marion Delcroix, et al.
Chest
|
February 5, 2021
Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study
Sean Gaine, Olivier Sitbon, Richard N Channick, et al.
European Journal of Heart Failure
|
November 22, 2021
The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study
Stephan Rosenkranz, Richard Channick, Kelly M Chin, et al.
Page
of 9
Search research articles
Search
Showing results (41-50 of 84) with videos related to
Sort By:
Page
of 9
Pulmonary Circulation
|
September 29, 2017
Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension
Jules Hernández-Sánchez, Louise Harlow, Colin Church, et al.
JHLT Open
|
January 22, 2026
Macitentan and phosphodiesterase-5 inhibitor alone or in combination in newly diagnosed pulmonary arterial hypertension: a pooled analysis
Vallerie V McLaughlin, Nicolas Sauvageot, Brian Hennessy, et al.
Plos One
|
April 10, 2015
Elevated plasma CXCL12α is associated with a poorer prognosis in pulmonary arterial hypertension
Brian N McCullagh, Christine M Costello, Lili Li, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation
|
November 16, 2025
Evaluating oral selexipag in pulmonary arterial hypertension: Insights on survival, safety, and dosing patterns from the complete observation period of GRIPHON and its open-label extension
Vallerie V McLaughlin, Luke Howard, Jean Elwing, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation
|
September 2, 2024
Changes in REVEAL Lite 2 risk status are associated with long-term outcomes in patients with pulmonary arterial hypertension: A post-hoc analysis of the GRIPHON study
Raymond L Benza, Kelly M Chin, Sean Gaine, et al.
Thrombosis and Haemostasis
|
January 17, 2025
Treatment of Venous Thromboembolism with Edoxaban over 18 Months: Results from ETNA-VTE Europe
Giancarlo Agnelli, Ulrich Hoffmann, Philippe Hainaut, et al.
Heart Rhythm
|
August 21, 2024
Improved diagnosis of arrhythmogenic right ventricular cardiomyopathy using electrocardiographic deep learning
Richard T Carrick, Eric D Carruth, Alessio Gasperetti, et al.
JHLT Open
|
March 27, 2025
Effects of macitentan and selexipag across prognostic age groups in patients with pulmonary arterial hypertension
Richard Channick, Sarah Medrek, Marion Delcroix, et al.
Chest
|
February 5, 2021
Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study
Sean Gaine, Olivier Sitbon, Richard N Channick, et al.
European Journal of Heart Failure
|
November 22, 2021
The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study
Stephan Rosenkranz, Richard Channick, Kelly M Chin, et al.
Page
of 9